Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILRB4 STAR-T Cells in R/R AML
NCT05518357Phase 1Completed
- Sponsor
- Lu Daopei Hospital
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- CAR-T Cells, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LILRB4 STAR-T in acute myeloid leukemia (AML), sponsored by Lu Daopei Hospital. Primary endpoint: Safety and Tolerability (DLT, AE, SAE, CRS, ICANS) at 12 months. Started Jun 2022; status: completed.
02
Drugs
LILRB4 STAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05518357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518357.